Inhibition of matrix metalloproteinase activity prevents increases in myocardial tumor necrosis factor-α

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 2, 2010, Pages 245-250

  Murray, David B ^b   Levick, Scott P ^a   Brower, Gregory L ^a   Janicki, Joseph S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Aortocaval fistula; Cytokines; GM6001; MMP; TNF ; Ventricular remodeling

Indexed keywords

COLLAGEN; ENDOTHELIN 1; ILOMASTAT; MATRIX METALLOPROTEINASE; NEDOCROMIL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTOCAVAL FISTULA; ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; CYTOKINE RELEASE; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE OVERLOAD; MALE; MAST CELL DEGRANULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RAT;

ANIMALS; CELL COUNT; CELL DEGRANULATION; CYTOKINES; EXTRACELLULAR MATRIX; MALE; MAST CELLS; MATRIX METALLOPROTEINASES; MYOCARDIUM; NEUROTRANSMITTER AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

FISTULA; RATTUS;

EID: 77953688654     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.04.005     Document Type: Article

References (51)

1. Hausenloy D.J., Yellon D.M. Clinical translation of cardioprotective strategies: report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection. Basic Res Cardiol Sep 2008, 103(5):493-500.
2. Li S., Zhong S., Zeng K., Luo Y., Zhang F., Sun X., et al. Blockade of NF-kappaB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats. Basic Res Cardiol Jan 2010, 105(1):139-150.
3. Chorianopoulos E., Heger T., Lutz M., Frank D., Bea F., Katus H.A., et al. FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol Mar 2010, 105(2):301-313.
4. Frantz S., Hu K., Adamek A., Wolf J., Sallam A., Maier S.K., et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol Sep 2008, 103(5):485-492.
5. Gallagher G., Menzie S., Huang Y., Jackson C., Hunyor S.N. Regional cardiac dysfunction is associated with specific alterations in inflammatory cytokines and matrix metalloproteinases after acute myocardial infarction in sheep. Basic Res Cardiol Jan 2007, 102(1):63-72.
6. Bozkurt B., Torre-Amione G., Warren M.S., Whitmore J., Soran O.Z., Feldman A.M., et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation Feb 27 2001, 103(8):1044-1047.
7. Conraads V.M., Vrints C.J., Rodrigus I.E., Hoymans V.Y., Van Craenenbroeck E.M., Bosmans J., et al. Depressed expression of MuRF1 and MAFbx in areas remote of recent myocardial infarction: a mechanism contributing to myocardial remodeling?. Basic Res Cardiol Mar 2010, 105(2):219-226.
8. Dorge H., Schulz R., Belosjorow S., Post H., van de Sand A., Konietzka I., et al. Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J Mol Cell Cardiol Jan 2002, 34(1):51-62.
9. Diwan A., Dibbs Z., Nemoto S., DeFreitas G., Carabello B.A., Sivasubramanian N., et al. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation Jan 20 2004, 109(2):262-268.
10. Skyschally A., Gres P., Hoffmann S., Haude M., Erbel R., Schulz R., et al. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res Jan 5 2007, 100(1):140-146.
11. Thielmann M., Dorge H., Martin C., Belosjorow S., Schwanke U., van De S.A., et al. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res Apr 19 2002, 90(7):807-813.
12. Frangogiannis N.G., Burns A.R., Michael L.H., Entman M.L. Histochemical and morphological characteristics of canine cardiac mast cells. Histochem J Apr 1999, 31(4):221-229.
13. Gilles S., Zahler S., Welsch U., Sommerhoff C.P., Becker B.F. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc Res Dec 1 2003, 60(3):608-616.
14. Frangogiannis N.G., Lindsey M.L., Michael L.H., Youker K.A., Bressler R.B., Mendoza L.H., et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation Aug 18 1998, 98(7):699-710.
15. Reil J.C., Gilles S., Zahler S., Brandl A., Drexler H., Hultner L., et al. Insights from knock-out models concerning postischemic release of TNFalpha from isolated mouse hearts. J Mol Cell Cardiol Jan 2007, 42(1):133-141.
16. Levick S.P., Gardner J.D., Holland M., Hauer-Jensen M., Janicki J.S., Brower G.L. Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. J Mol Cell Cardiol Jul 2008, 45(1):56-61.
17. Chen Y., Pat B., Zheng J., Cain L., Powell P., Shi K., et al. Tumor necrosis factor-alpha produced in cardiomyocytes mediates a predominant myocardial inflammatory response to stretch in early volume overload. J Mol Cell Cardiol Jan 4 2010.
18. Moss M.L., Bartsch J.W. Therapeutic benefits from targeting of ADAM family members. Biochemistry Jun 15 2004, 43(23):7227-7235.
19. Levy D.E., Lapierre F., Liang W., Ye W., Lange C.W., Li X., et al. Matrix metalloproteinase inhibitors: a structure-activity study. J Med Chem Jan 15 1998, 41(2):199-223.
20. Murray D.B., Gardner J.D., Levick S.P., Brower G.L., Morgan L.G., Janicki J.S. Response of cardiac mast cells to atrial natriuretic peptide. Am J Physiol Heart Circ Physiol Aug 2007, 293(2):H1216-H1222.
21. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature Feb 20 1997, 385(6618):733-736.
22. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature Feb 20 1997, 385(6618):729-733.
23. Brower G.L., Janicki J.S. Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. J Card Fail Sep 2005, 11(7):548-556.
24. Brower G.L., Chancey A.L., Thanigaraj S., Matsubara B.B., Janicki J.S. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol Aug 2002, 283(2):H518-H525.
25. Mirastschijski U., Haaksma C.J., Tomasek J.J., Agren M.S. Matrix metalloproteinase inhibitor GM 6001 attenuates keratinocyte migration, contraction and myofibroblast formation in skin wounds. Exp Cell Res Oct 1 2004, 299(2):465-475.
26. Lu L., Gunja-Smith Z., Woessner J.F., Ursell P.C., Nissen T., Galardy R.E., et al. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol Heart Circ Physiol Aug 2000, 279(2):H601-H609.
27. Moss M.L., Rasmussen F.H. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem Jul 15 2007, 366(2):144-148.
28. Murray D.B., Gardner J.D., Brower G.L., Janicki J.S. Effects of nonselective endothelin-1 receptor antagonism on cardiac mast cell-mediated ventricular remodeling in rats. Am J Physiol Heart Circ Physiol Mar 2008, 294(3):H1251-H1257.
29. Murray D.B., Gardner J.D., Brower G.L., Janicki J.S. Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats. Am J Physiol Heart Circ Physiol Nov 2004, 287(5):H2295-H2299.
30. Morgan L.G., Levick S.P., Voloshenyuk T.G., Murray D.B., Forman M.F., Brower G.L., et al. A novel technique for isolating functional mast cells from the heart. Inflamm Res May 2008, 57(5):241-246.
31. Bozkurt B., Kribbs S.B., Clubb F.J., Michael L.H., Didenko V.V., Hornsby P.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation Apr 14 1998, 97(14):1382-1391.
32. Matsumoto H., Koga H., Iida M., Tarumi K., Fujita M., Haruma K. Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats. Scand J Gastroenterol Nov 2006, 41(11):1320-1329.
33. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol Mar 1998, 274(3 Pt 2):R577-R595.
34. Kapadia S., Lee J., Torre-Amione G., Birdsall H.H., Ma T.S., Mann D.L. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest Aug 1995, 96(2):1042-1052.
35. D'Ortho M.P., Will H., Atkinson S., Butler G., Messent A., Gavrilovic J., et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem Dec 15 1997, 250(3):751-757.
36. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J.M., Crimmin M., et al. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol May 1995, 57(5):774-777.
37. Chancey A.L., Brower G.L., Janicki J.S. Cardiac mast cell-mediated activation of gelatinase and alteration of ventricular diastolic function. Am J Physiol Heart Circ Physiol Jun 2002, 282(6):H2152-H2158.
38. Jobe L.J., Melendez G.C., Levick S.P., Du Y., Brower G.L., Janicki J.S. TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am J Physiol Heart Circ Physiol Oct 2009, 297(4):H1462-H1468.
39. Levick S.P., Gardner J.D., Holland M., Hauer-Jensen M., Janicki J.S., Brower G.L. Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. J Mol Cell Cardiol Jul 2008, 45(1):56-61.
40. Murray D.B., McMillan R., Brower G.L., Janicki J.S. ETA selective receptor antagonism prevents ventricular remodeling in volume-overloaded rats. Am J Physiol Heart Circ Physiol Jul 2009, 297(1):H109-H116.
41. Yan A.T., Yan R.T., Spinale F.G., Afzal R., Gunasinghe H.R., Stroud R.E., et al. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail Feb 2008, 10(2):125-128.
42. Tang X.Y., Liu Q., Dai D.Z., Dai Y. CPU0213, a novel endothelin receptor antagonist, suppresses the upregulation of matrix metalloproteinases and connexin 43 in hyperthyroid myocardium. Pharmacol Rep Jul 2008, 60(4):524-531.
43. Deschamps A.M., Zavadzkas J., Murphy R.L., Koval C.N., McLean J.E., Jeffords L., et al. Interruption of endothelin signaling modifies membrane type 1 matrix metalloproteinase activity during ischemia and reperfusion. Am J Physiol Heart Circ Physiol Feb 2008, 294(2):H875-H883.
44. Podesser B.K., Siwik D.A., Eberli F.R., Sam F., Ngoy S., Lambert J., et al. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol Mar 2001, 280(3):H984-H991.
45. Ozdemir R., Parlakpinar H., Polat A., Colak C., Ermis N., Acet A. Selective endothelin a (ET(A)) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology Feb 15 2006, 219(1-3):142-149.
46. Spruill L.S., Lowry A.S., Stroud R.E., Squires C.E., Mains I.M., Flack E.C., et al. Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy. Am J Physiol Cell Physiol Oct 2007, 293(4):C1362-C1373.
47. Matsushima H., Yamada N., Matsue H., Shimada S. The effects of endothelin-1 on degranulation, cytokine, and growth factor production by skin-derived mast cells. Eur J Immunol Jul 2004, 34(7):1910-1919.
48. Coulombe M., Battistini B., Stankova J., Pouliot P., Bissonnette E.Y. Endothelins regulate mediator production of rat tissue-cultured mucosal mast cells. Up-regulation of Th1 and inhibition of Th2 cytokines. J Leukoc Biol May 2002, 71(5):829-836.
49. Maurer M., Wedemeyer J., Metz M., Piliponsky A.M., Weller K., Chatterjea D., et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature Nov 25 2004, 432(7016):512-516.
50. Metsarinne K.P., Vehmaan-Kreula P., Kovanen P.T., Saijonmaa O., Baumann M., Wang Y., et al. Activated mast cells increase the level of endothelin-1 mRNA in cocultured endothelial cells and degrade the secreted Peptide. Arterioscler Thromb Vasc Biol Feb 1 2002, 22(2):268-273.
51. Fernandez-Patron C., Radomski M.W., Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res Nov 12 1999, 85(10):906-911.